Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, providing a corporate update on its lead clinical programs, CUE-101 and CUE-102, as well as its lead preclinical autoimmune program partnered with Ono Pharmaceutical. The presentation will also cover market opportunities, competitive positioning, and key forecasted value-driving 2024 milestones.

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the latest developments from its lead clinical programs, CUE-101 and CUE-102, its lead preclinical autoimmune program partnered with Ono Pharmaceutical, as well as market opportunities, competitive positioning and key forecasted value-driving 2024 milestones.

Presentation Details
Oppenheimer 34th Annual Healthcare Life Sciences Conference
Date and Time: Tuesday, February 13, 9:20 a.m. EST
Webcast Link: https://wsw.com/webcast/oppenheimer33/cue/2534426
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on Twitter and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com

When will Cue Biopharma present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

Cue Biopharma will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference from February 13-14, 2024.

What are Cue Biopharma's lead clinical programs?

Cue Biopharma's lead clinical programs are CUE-101 and CUE-102.

Who will be presenting at the conference from Cue Biopharma?

Daniel Passeri, M.Sc., J.D., the chief executive officer of Cue Biopharma, will be presenting at the conference.

Where can the webcast of the presentation be accessed?

The live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com.